Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2025)

Inhibrx Biosciences (INBX) reported Non-Current Debt of $100.6 million for Q4 2025, up 0.64% quarter-over-quarter from $99.9 million in Q3 2025.

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2025) Analysis & Trends

Inhibrx Biosciences (INBX) has 2 years of Non-Current Debt data on file, last reported at $100.6 million in Q4 2025.

Non-Current Debt for Q4 2025 came in at $100.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $100.6 million (changed N/A YoY), and the FY2025 annual result was $100.6 million, changed N/A from the prior year.
Non-Current Debt grew to $100.6 million in Q4 2025 per INBX's latest filing, from $99.9 million in the prior quarter.
Over five years, Non-Current Debt peaked at $207.0 million in Q4 2023 and troughed at $98.7 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Inhibrx Biosciences	186.16 Mn	186.16 Mn	-	100.56 Mn

Download Data